Business Description
NextCell Pharma AB
ISIN : SE0009723125
Total Employee Number:
24Compare
Compare
Traded in other countries / regions
NXTCL.Sweden65G.Germany IPO Date
2017-07-13Description
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.79 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -1.09 | |||||
Beneish M-Score | -4.16 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.8 | |||||
3-Year EBITDA Growth Rate | 18.3 | |||||
3-Year EPS without NRI Growth Rate | 17.4 | |||||
3-Year FCF Growth Rate | 18.2 | |||||
3-Year Book Growth Rate | -39.2 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.18 | |||||
9-Day RSI | 41.34 | |||||
14-Day RSI | 44.08 | |||||
3-1 Month Momentum % | -13.33 | |||||
6-1 Month Momentum % | -25.99 | |||||
12-1 Month Momentum % | -22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.16 | |||||
Quick Ratio | 5.12 | |||||
Cash Ratio | 3.24 | |||||
Days Inventory | 20.31 | |||||
Days Sales Outstanding | 99.53 | |||||
Days Payable | 130.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -36.8 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 10.72 | |||||
Operating Margin % | -420.13 | |||||
Net Margin % | -413.92 | |||||
EBITDA Margin % | -388.53 | |||||
FCF Margin % | -408.76 | |||||
OCF Margin % | -358.48 | |||||
ROE % | -78.09 | |||||
ROA % | -64.3 | |||||
ROIC % | -123.93 | |||||
3-Year ROIIC % | -8.68 | |||||
ROC (Joel Greenblatt) % | -298.7 | |||||
ROCE % | -71.67 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.78 | |||||
PB Ratio | 2.22 | |||||
Price-to-Tangible-Book | 2.24 | |||||
EV-to-EBIT | -2.12 | |||||
EV-to-EBITDA | -2.25 | |||||
EV-to-Revenue | 8.75 | |||||
EV-to-FCF | -2.14 | |||||
Price-to-GF-Value | 1.12 | |||||
| Price-to-Net-Current-Asset-Value | 4.04 | |||||
| Price-to-Net-Cash | 9.18 | |||||
Earnings Yield (Greenblatt) % | -47.17 | |||||
FCF Yield % | -35.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NextCell Pharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 9.878 | ||
| EPS (TTM) (kr) | -0.45 | ||
| Beta | 1.7595 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.03 | ||
| Volatility % | 94 | ||
| 14-Day RSI | 44.08 | ||
| 14-Day ATR (kr) | 0.079978 | ||
| 20-Day SMA (kr) | 1.0354 | ||
| 12-1 Month Momentum % | -22 | ||
| 52-Week Range (kr) | 0.63 - 1.784 | ||
| Shares Outstanding (Mil) | 111.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NextCell Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NextCell Pharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-26 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-27 | In 31 days | ||
| First quarter earnings results for 2026 | 2026-05-28 | 1.28 (+0.16%) | ||
| General meeting for 2025 | 2026-05-27 10:00 | 1.28 (+1.75%) | ||
| Annual report for 2025 | 2026-05-15 | 1.08 (-6.57%) | ||
| Fourth quarter earnings results for 2025 | 2025-10-30 | 0.89 (-8.15%) | ||
| Third quarter earnings results for 2025 | 2025-07-24 | 1.15 (+6.10%) | ||
| Second quarter earnings results for 2025 | 2025-04-25 | 1.15 (-1.04%) | ||
| First quarter earnings results for 2025 | 2025-01-30 | 2.88 (-4.00%) | ||
| General meeting for 2024 | 2024-11-27 | 1.69 (+0.60%) |
Show
Entries
NextCell Pharma AB Frequently Asked Questions
What is NextCell Pharma AB(OSTO:NXTCL)'s stock price today?
The current price of OSTO:NXTCL is kr1.01. The 52 week high of OSTO:NXTCL is kr1.78 and 52 week low is kr0.63.
When is next earnings date of NextCell Pharma AB(OSTO:NXTCL)?
The next earnings date of NextCell Pharma AB(OSTO:NXTCL) is 2026-08-27.
Does NextCell Pharma AB(OSTO:NXTCL) pay dividends? If so, how much?
NextCell Pharma AB(OSTO:NXTCL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on NextCell Pharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers